ATE390138T1 - Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung - Google Patents

Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung

Info

Publication number
ATE390138T1
ATE390138T1 AT06250764T AT06250764T ATE390138T1 AT E390138 T1 ATE390138 T1 AT E390138T1 AT 06250764 T AT06250764 T AT 06250764T AT 06250764 T AT06250764 T AT 06250764T AT E390138 T1 ATE390138 T1 AT E390138T1
Authority
AT
Austria
Prior art keywords
formulation
extended release
dipyridamol
production
compositions containing
Prior art date
Application number
AT06250764T
Other languages
English (en)
Inventor
Minutza Leibovici
Itamar Kanari
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE390138T1 publication Critical patent/ATE390138T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06250764T 2006-02-09 2006-02-13 Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung ATE390138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77225706P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
ATE390138T1 true ATE390138T1 (de) 2008-04-15

Family

ID=36384355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06250764T ATE390138T1 (de) 2006-02-09 2006-02-13 Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung

Country Status (13)

Country Link
US (1) US20070184110A1 (de)
EP (1) EP1820506B1 (de)
JP (1) JP2008534681A (de)
CN (1) CN101365453A (de)
AT (1) ATE390138T1 (de)
AU (1) AU2006337643A1 (de)
CA (1) CA2640472A1 (de)
DE (1) DE602006000819T2 (de)
DK (1) DK1820506T3 (de)
ES (1) ES2303314T3 (de)
IL (1) IL193023A0 (de)
PT (1) PT1820506E (de)
WO (1) WO2007092026A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
CN101780037B (zh) * 2010-02-03 2011-11-16 南昌大学 双嘧达莫自乳化给药系统及其制备方法
CN101919822B (zh) * 2010-07-16 2013-10-23 钟术光 综合性能改善的片剂及其制备方法
EP2704698B1 (de) * 2011-05-05 2019-10-02 Hennig Arzneimittel GmbH&Co. Kg Arzneiform zur gezielten freigabe von wirkstoffen
BR112014020474B1 (pt) * 2012-02-21 2022-03-29 Esteve Pharmaceuticals, S.A. Composições farmacêuticas orais de etexilato de dabigatrana
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN103417494B (zh) * 2013-08-13 2015-12-23 杭州高成生物营养技术有限公司 一种以酒石酸作为主要成分的微丸
MX375936B (es) * 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
CN105106225A (zh) * 2015-09-10 2015-12-02 石家庄市智同医药科技有限公司 一种复方双嘧达莫阿司匹林片剂及其制备方法
EP4247354A4 (de) * 2020-11-18 2025-02-19 Fb-Hrs, Llc Zusammensetzungen mit dofetilid und mexiletin und verwendungen davon
CN117442628A (zh) * 2023-10-27 2024-01-26 浙江歌文达生物医药科技有限公司 一种含有缓释双嘧达莫微片的速释阿司匹林包衣胶囊及其制备方法
CN118384120B (zh) * 2024-05-09 2025-07-25 山东康美乐医药科技有限公司 一种恩格列净二甲双胍缓释片剂及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
DE2831164A1 (de) * 1978-07-15 1980-01-24 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
EP0169465B1 (de) * 1984-07-21 1990-02-28 Hoechst Aktiengesellschaft Kombinationspräparat aus Pyrimido-pyrimidinen und O-Acetylsalicylsäure bzw. deren pharmakologisch verträglichen Salzen und dessen Verwendung
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
EP1093814A1 (de) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Also Published As

Publication number Publication date
HK1104791A1 (en) 2008-01-25
US20070184110A1 (en) 2007-08-09
ES2303314T3 (es) 2008-08-01
CN101365453A (zh) 2009-02-11
DE602006000819D1 (de) 2008-05-08
CA2640472A1 (en) 2007-08-16
AU2006337643A1 (en) 2007-08-16
IL193023A0 (en) 2009-02-11
WO2007092026A1 (en) 2007-08-16
DK1820506T3 (da) 2008-07-07
DE602006000819T2 (de) 2009-04-09
PT1820506E (pt) 2008-05-23
EP1820506B1 (de) 2008-03-26
JP2008534681A (ja) 2008-08-28
EP1820506A1 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
IL193023A0 (en) Dipyridamole extended-release formulations and process for preparing same
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
IL192670A (en) Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication
ATE418327T1 (de) Pharmazeutische granulatzusammensetzungen mit sofortiger freisetzung und kontinuierliches verfahren zu ihrer herstellung
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
WO2008063300A3 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
JP2007523049A5 (de)
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
FI20055568A0 (fi) Menetelmä karboksyylihappoesteriseoksien valmistamiseksi ja niiden käyttö
ITMI20020731A0 (it) Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ZA200805563B (en) Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
ZA200902451B (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
ATE457719T2 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
ATE415148T1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
ATE471930T1 (de) 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
ATE374172T1 (de) Hexensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
WO2009059717A3 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
JP2008515980A5 (de)
ATE336230T1 (de) Orale pharmazeutische zusammensetzung und verfahren zu ihrer herstellung
DE602004005734D1 (de) Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
ATE503749T1 (de) Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
FI20020593A0 (fi) Menetelmä konjugoidun linolihapon valmistamiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties